Evidence map›Paper›PMID 42122196›Full record

ArticleCancers2026

Selecting Representative Tumour Bed Slices May Allow Reduced Embedding Without Loss of Accuracy in Response Evaluation to Neoadjuvant Immunotherapy in Stage IIIB/C Cutaneous Melanoma.

Anders Bergström, Axel Nelson, Anne Huibers, Emel Cicek, Åse Silverdal, Martin E Johansson, Katarzyna Lundmark, Jonas Selling, Anders Muszta, Iva Johansson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anders BergströmVästra Götalandsregionen, Department of Clinical Pathology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden.ORCID 0009-0007-1394-0893
Axel NelsonVästra Götalandsregionen, Department of Oncology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden.
Anne HuibersInstitute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, P.O. Box 400, SE40530 Gothenburg, Sweden.
Emel CicekVästra Götalandsregionen, Department of Clinical Pathology, Södra Älvsborgs Sjukhus, SE50182 Borås, Sweden.
Åse SilverdalVästra Götalandsregionen, Department of Clinical Pathology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden.
Martin E JohanssonVästra Götalandsregionen, Department of Clinical Pathology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden.ORCID 0000-0001-8510-3102
Katarzyna LundmarkDepartment of Clinical Pathology, Linköping University Hospital, SE58185 Linköping, Sweden.
Jonas SellingStatistikakademin AB, SE75321 Uppsala, Sweden.
Anders MusztaSahlgrenska Academy and School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, P.O. Box 400, SE40530 Gothenburg, Sweden.
Iva JohanssonVästra Götalandsregionen, Department of Clinical Pathology, Sahlgrenska University Hospital, SE41335 Gothenburg, Sweden.ORCID 0000-0002-9683-4637

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

melanomaneoadjuvant immunotherapypathological responseresidual viable tumourtumour bed

Identifiers

PMID42122196
PMCPMC13162578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.